Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluticasone furoate/Vilanterol - GlaxoSmithKline/Innoviva

Drug Profile

Fluticasone furoate/Vilanterol - GlaxoSmithKline/Innoviva

Alternative Names: '444/'698; 444/698; Breo Ellipta; FF/GW642444; FF/VI; Fluticasone furoate/GW642444; Fluticasone furoate/vilanterol trifenatate; Fluticasone-furoate/vilanterol; GSK-2285997; GW642444/GW685698; GW642444M/GW685698X; GW685698/GW642444; GW685698X/GW642444M; Relovair; Relvar Ellipta; Revinty Ellipta

Latest Information Update: 10 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Androstadienes; Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorobenzenes; Ethers; Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 06 May 2019 United States District Court for the District of Delaware validates patent infringement case filed against GlaxoSmithKline by Vectura for its US patent 8303991
  • 02 May 2019 Efficacy data from the phase III CAPTAIN trial in Asthma released by GlaxoSmithKline
  • 22 Feb 2019 GlaxoSmithKline completes the phase IIII CAPTAIN trial for Asthma in US, Argentina, Australia, Canada, Germany, Italy, Japan, South Korea, Netherlands, Poland, Romania, Russia, South Africa, Spain, and United Kingdom (Inhalation) (NCT02924688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top